216 related articles for article (PubMed ID: 31279493)
1. Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
Matsuo K; Huang Y; Zivanovic O; Shimada M; Machida H; Grubbs BH; Roman LD; Wright JD
Gynecol Oncol; 2019 Sep; 154(3):505-515. PubMed ID: 31279493
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer.
Matsuo K; Machida H; Yamagami W; Ebina Y; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Enomoto T; Mikami M
Obstet Gynecol; 2019 Nov; 134(5):1017-1026. PubMed ID: 31599824
[TBL] [Abstract][Full Text] [Related]
3. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
Matsuo K; Machida H; Mandelbaum RS; Grubbs BH; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2019 May; 153(2):230-237. PubMed ID: 30797590
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
Nasioudis D; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA
Gynecol Oncol; 2019 Aug; 154(2):302-307. PubMed ID: 31155308
[TBL] [Abstract][Full Text] [Related]
5. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
6. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
Lydiksen L; Jensen-Fangel S; Blaakaer J
Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
[TBL] [Abstract][Full Text] [Related]
7. Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study.
Kajiyama H; Suzuki S; Yoshikawa N; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():131-136. PubMed ID: 30685661
[TBL] [Abstract][Full Text] [Related]
8. Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
Richardson MT; Mysona DP; Klein DA; Mann A; Liao CI; Diver EJ; Darcy KM; Tian C; She JX; Ghamande S; Van Le L; Kapp DS; Chan JK
Gynecol Oncol; 2020 Oct; 159(1):118-128. PubMed ID: 32828578
[TBL] [Abstract][Full Text] [Related]
9. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.
Asare EA; Compton CC; Hanna NN; Kosinski LA; Washington MK; Kakar S; Weiser MR; Overman MJ
Cancer; 2016 Jan; 122(2):213-21. PubMed ID: 26506400
[TBL] [Abstract][Full Text] [Related]
10. Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer.
Matsuo K; Machida H; Mariani A; Mandelbaum RS; Glaser GE; Gostout BS; Roman LD; Wright JD
J Gynecol Oncol; 2018 Sep; 29(5):e69. PubMed ID: 30022633
[TBL] [Abstract][Full Text] [Related]
11. Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.
Kumar A; Le N; Gilks CB; Santos JL; Wong F; Swenerton K; Hoskins PJ; McAlpine JN; Tinker AV
Int J Gynecol Cancer; 2017 Nov; 27(9):1819-1825. PubMed ID: 28930809
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma.
Hsieh SF; Lau HY; Wu HH; Hsu HC; Twu NF; Cheng WF
Int J Environ Res Public Health; 2019 Feb; 16(4):. PubMed ID: 30795566
[TBL] [Abstract][Full Text] [Related]
14. Comparison of stage III mucinous and serous ovarian cancer: a case-control study.
Firat Cuylan Z; Karabuk E; Oz M; Turan AT; Meydanli MM; Taskin S; Sari ME; Sahin H; Ulukent SC; Akbayir O; Gungorduk K; Gungor T; Kose MF; Ayhan A
J Ovarian Res; 2018 Oct; 11(1):91. PubMed ID: 30376858
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of pelvic and para-aortic lymphadenectomy on clinically-apparent stage I primary mucinous epithelial ovarian carcinoma: a multi-institutional study with propensity score-weighted analysis.
Yoshihara M; Kajiyama H; Tamauchi S; Iyoshi S; Yokoi A; Suzuki S; Kawai M; Nagasaka T; Takahashi K; Matsui S; Kikkawa F
Jpn J Clin Oncol; 2020 Feb; 50(2):145-151. PubMed ID: 31688935
[TBL] [Abstract][Full Text] [Related]
17. Evolving population-based statistics for rare epithelial ovarian cancers.
Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
[TBL] [Abstract][Full Text] [Related]
18. Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
Cham S; Huang Y; Melamed A; Worley MJ; Hou JY; Tergas AI; Khoury-Collado F; Gockley A; Clair CMST; Hershman DL; Wright JD
Gynecol Oncol; 2021 Jul; 162(1):56-64. PubMed ID: 33965245
[TBL] [Abstract][Full Text] [Related]
19. International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers.
Mueller JJ; Lajer H; Mosgaard BJ; Bach Hamba S; Morice P; Gouy S; Hussein Y; Soslow RA; Schlappe BA; Zhou QC; Iasonos A; Høgdall C; Leary A; O'Cearbhaill RE; Abu-Rustum NR
Int J Gynecol Cancer; 2018 Jun; 28(5):915-924. PubMed ID: 29561302
[TBL] [Abstract][Full Text] [Related]
20. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
